Male Health

New prostate cancer risk prediction tool identifies men at highest risk

Prostate cancer is the fourth most common cancer worldwide and the most common cancer among men in the UK. In…

Tavanta concludes subject enrolment in Phase III prostate cancer trial

Tavanta Therapeutics has concluded subject enrolment in its pivotal Phase III clinical trial of TAVT-45 (abiraterone acetate) granules for oral…

Increase in prostate cancer screening after rollout of revised national guidelines

In May 2018, the US Preventive Services Task Force (USPSTF) published new prostate cancer screening guidelines, which had last been…

Slow progress for male contraceptive trials

Within the pharmaceutical sphere, it is commonly known that the development of reversible male contraception has been extremely difficult. Options…

Astellas-Pfizer’s Xtandi reduces mortality risk in prostate cancer trial

Astellas Pharma and Pfizer have reported that their drug Xtandi (enzalutamide) enhanced overall survival (OS) in the Phase III ARCHES…

Pfizer initiates dosing in Phase III prostate cancer drug trial

Pfizer has dosed the first subject in a Phase III TALAPRO-3 clinical trial of oral drug talazoparib plus enzalutamide in…

Telix begins Phase III prostate cancer treatment trial

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant…

Can Merck overcome challenges in an immunologically “cold” tumour with Keytruda for prostate cancer?

Immuno-oncology represents a third major wave of strategies to treat cancer, after chemotherapy and targeted therapy. Some tumours, such as…

AstraZeneca and MSD report positive data from trial of Lynparza

AstraZeneca and MSD have reported positive results from the Phase III PROfound trial evaluating the safety and efficacy of Lynparza…

Sophiris Bio receives positive feedback for prostate cancer trial

Late-stage clinical biopharmaceutical company Sophiris Bio has received positive feedback from the European Medicines Agency (EMA) for the Phase III…